Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

REGN

Regeneron Pharmaceuticals, Inc

Feb 13 • 12:48PM ET

802.72

+19.07 2.43 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV IBB XLV JEPI QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	19.31	EPS (ttm)	41.56	Insider Own	3.74%	Shs Outstand	103.90M	Perf Week	2.19%
Market Cap	84.85B	Forward P/E	15.23	EPS next Y	52.71	Insider Trans	-0.29%	Shs Float	101.75M	Perf Month	6.44%
Enterprise Value	79.21B	PEG	1.38	EPS next Q	9.16	Inst Own	84.30%	Short Float	2.14%	Perf Quarter	17.75%
Income	4.50B	P/S	5.92	EPS this Y	2.30%	Inst Trans	-0.61%	Short Ratio	2.28	Perf Half Y	41.83%
Sales	14.34B	P/B	2.71	EPS next Y	16.29%	ROA	11.49%	Short Interest	2.18M	Perf YTD	4.00%
Book/sh	295.71	P/C	9.85	EPS next 5Y	11.05%	ROE	14.87%	52W High	821.11 -2.24%	Perf Year	19.05%
Cash/sh	81.46	P/FCF	20.79	EPS past 3/5Y	2.76% 6.33%	ROIC	13.18%	52W Low	476.49 68.47%	Perf 3Y	5.07%
Dividend Est.	2.65 (0.33%)	EV/EBITDA	18.66	Sales past 3/5Y	5.62% 11.04%	Gross Margin	81.56%	Volatility	3.25% 2.91%	Perf 5Y	65.30%
Dividend TTM	3.52 (0.44%)	EV/Sales	5.52	EPS Y/Y TTM	5.49%	Oper. Margin	25.81%	ATR (14)	23.13	Perf 10Y	111.79%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	3.39	Sales Y/Y TTM	0.99%	Profit Margin	31.41%	RSI (14)	61.54	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	4.13	EPS Q/Q	-2.57%	SMA20	5.32%	Beta	0.40	Target Price	875.67
Payout	8.49%	Debt/Eq	0.10	Sales Q/Q	2.51%	SMA50	5.64%	Rel Volume	0.62	Prev Close	783.65
Employees	15410	LT Debt/Eq	0.09	Earnings	Jan 30 BMO	SMA200	27.77%	Avg Volume	955.45K	Price	802.72
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.56% 1.93%	Trades		Volume	315,051	Change	2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy	$860
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800

Show Previous Ratings

Today 10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
09:57AM	Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? (Insider Monkey)
08:23AM	Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors (Benzinga)
Feb-12-26 11:08AM	Sanofi Shares Fall After CEO Change (The Wall Street Journal)
09:44AM	Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson (Investor's Business Daily)
09:30AM	Loading…
09:30AM	Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? (Zacks)
Feb-11-26 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
04:56AM	The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL (Zacks)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:14PM	Top Stock Reports for NVIDIA, Amazon & Regeneron (Zacks)
04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily)
09:07AM	Evommune Nearly Doubles Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy (GlobeNewswire)
Feb-06-26 09:26AM	Have originator medicines list prices started to drop in the US? (Pharmaceutical Technology)
04:17PM	Loading…
Feb-05-26 04:17PM	TrumpRx's launch is hours away. Here's why it may not lower drug prices for most Americans. (MarketWatch)
12:48PM	Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right. (Barrons.com)
Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
12:27PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
Feb-03-26 10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
Feb-02-26 06:08PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases (GlobeNewswire)
Jan-31-26 04:37PM	Regeneron (REGN) Draws Higher Target From TD Cowen (Insider Monkey)
12:35PM	Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines (Insider Monkey)
Jan-30-26 04:09PM	Regeneron Falls, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles (Investor's Business Daily)
04:02PM	Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
11:28AM	Regeneron Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
11:15AM	Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season (Investor's Business Daily)
10:56AM	Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory (Benzinga)
10:30AM	Loading…
10:30AM	Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
10:25AM	REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth (Zacks)
10:22AM	Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles (Investor's Business Daily)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
07:56AM	Sanofi touts strong new launch sales amid looming Dupixent patent expiry (Pharmaceutical Technology)
07:40AM	Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:47AM	Regeneron: Q4 Earnings Snapshot (Associated Press Finance)
06:40AM	Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 (StockStory)
06:30AM	Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
04:19AM	Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week (The Wall Street Journal)
Jan-29-26 05:22PM	Analyst Report: Sanofi (Morningstar Research)
12:09PM	Sanofi Edges Higher As Immunology Powerhouse, Dupixent, Wallops Forecasts (Investor's Business Daily)
11:21AM	Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026 (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:21AM	Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN) (Insider Monkey)
08:20AM	PINKs 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything (24/7 Wall St.)
03:54AM	Apple, Oil Earnings, Inflation Data: Still to Come This Week (The Wall Street Journal)
Jan-28-26 10:03PM	Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow (StockStory)
11:24AM	Amgen Set to Report Q4 Earnings: What Investors Should Know (Zacks)
09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
09:46AM	Regeneron (REGN) Posted Solid Q3 Results, Eyes 2026 Pipeline Catalysts (Insider Monkey)
Jan-26-26 10:00AM	Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:20AM	Tesla, Microsoft, Meta, SanDisk And More: Stocks With Earnings This Week (Benzinga)
Jan-25-26 07:52AM	Big Tech earnings, Fed meeting feature as markets end January with busiest week of Q1: What to watch (Yahoo Finance)
04:46AM	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI (Investing.com)
Jan-23-26 07:00PM	Mag 7 earnings, Fed's rate decision: What to Watch (Yahoo Finance Video)
11:40AM	REGN or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
10:00AM	Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
01:25PM	2 Healthcare Stocks Poised for a Comeback in 2026 (Motley Fool)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-21-26 12:00PM	Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search (GlobeNewswire)
06:39AM	Corvus shares nearly triple on positive data for eczema pill (BioPharma Dive)
Jan-20-26 08:36AM	Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case (Zacks)
08:28AM	Should You Be Excited for Regeneron (REGN)? (Insider Monkey)
Jan-19-26 03:23PM	Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (MarketBeat)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
08:32AM	ANIP Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 02:05PM	JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries (Pharmaceutical Technology)
12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
Jan-13-26 03:22PM	Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs (Bloomberg)
12:57PM	AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions (GuruFocus.com)
Jan-12-26 08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Jan-11-26 08:31PM	A big Wall Street flip just changed the Regeneron narrative (TheStreet)
Jan-09-26 04:52PM	Top Research Reports for NVIDIA, Alphabet & Amazon.com (Zacks)
12:00PM	Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga)
Jan-07-26 04:18PM	Regeneron Just Moved From Underperform To Buy - Here's Why (Benzinga)
04:05PM	Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. (Barrons.com)
12:10PM	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
11:20AM	Why Regeneron (REGN) Stock Is Trading Up Today (StockStory)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
07:37AM	BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts (Investing.com)
Jan-06-26 11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
07:18AM	Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know (Barchart)
05:30AM	Big Pharma Has More Going for It Than Obesity Drugs (The Wall Street Journal)
04:40AM	The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson (Zacks)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
07:41AM	Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 (Zacks)
Jan-02-26 04:05PM	Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 (GlobeNewswire)
09:53AM	Will ANIP's Rare Disease Franchise Maintain Momentum in 2026? (Zacks)
08:40AM	REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? (Zacks)
Dec-31-25 08:10AM	BAYRY's 2025 Revival: Will the Momentum Continue in 2026? (Zacks)
01:30AM	It's Earnings Warning Season. How to Profit From Others' Misery. (Barrons.com)
Dec-30-25 11:04PM	3 Reasons to Avoid REGN and 1 Stock to Buy Instead (StockStory)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pitofsky Jason	SVP Controller	Feb 09 '26	Option Exercise	492.00	1,000	492,000	6,308	Feb 11 04:03 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Sale	778.52	2,036	1,585,058	4,272	Feb 11 04:03 PM
RYAN ARTHUR F	Director	Feb 09 '26	Sale	778.53	100	77,853	17,803	Feb 11 04:02 PM
Arthur F. Ryan	Director	Feb 09 '26	Proposed Sale	785.51	400	314,204		Feb 09 05:02 PM
Pitofsky Jason	Officer	Feb 09 '26	Proposed Sale	783.17	2,036	1,594,534		Feb 09 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Option Exercise	374.12	1,500	561,180	3,203	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Sale	800.00	1,500	1,200,000	1,703	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Proposed Sale	800.00	1,500	1,200,000		Jan 07 12:03 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 31 '25	Option Exercise	0.00	28,570	0	339,030	Jan 05 05:54 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 31 '25	Option Exercise	0.00	28,570	0	243,093	Jan 05 05:53 PM
SING GEORGE L	Director	Dec 30 '25	Option Exercise	520.01	9,212	4,790,332	37,040	Dec 31 05:05 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 09 '25	Option Exercise	555.67	146,815	81,580,691	442,334	Dec 11 04:27 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 09 '25	Option Exercise	555.67	172,723	95,976,989	369,668	Dec 11 04:23 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience